Role of HLA compatibility in pediatric living-related liver transplantation

Transplantation

Volumn 74, Issue 8, 2002, Pages 1175-1180

  Kasahara, Mureo ^a   Kiuchi, Tetsuya ^a   Uryuhara, Kenji ^a   Uemoto, Shinji ^a   Fujimoto, Yasuhiro ^a   Ogura, Yasuhiro ^a   Oike, Fumitaka ^a   Kaihara, Satoshi ^a   Egawa, Hiroto ^a   Tanaka, Koichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; STEROID; TACROLIMUS;

ADOLESCENT; ALLOGRAFT; ARTICLE; BLOOD COMPATIBILITY; CADAVER; CHILD; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; STATISTICAL SIGNIFICANCE;

EID: 0037184338     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210270-00020     Document Type: Article

References (49)

1. Lark JR. Changing indications for liver transplantation. Gastroenterol Clin North Am 1993; 22: 213-229.
2. Terasaki PI, Cecka JM, eds. Clinical Transplants 1999. Los Angeles, UCLA Tissue Typing Laboratory 2000, pp 667-781.
3. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715.
4. Donaldson PT, Alexander GJM, O'Grady J, et al. Evidence for an immune response to HLA class I antigens in the vanishing-bile duct syndrome after liver transplantation. Lancet 1987; 1: 945-948.
5. O'Grady JG, Alexander GJM, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988; 2: 302-305.
6. Markus BH, Duquesnoy RJ, Gordon RD, et al. Histocompatibility and liver transplant outcome. Transplantation 1988; 46: 372-377.
7. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Transplantation 1994; 58: 786-792.
8. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation Hepatology. 1998; 27: 926-933.
9. Yagihashi A, Kobayashi M, Noguchi K, et al. HLA matching effect in liver transplantation. Transplant Proc 1992; 24: 2432-2433.
10. Francavilla R, Hadzic N, Underhill J, et al. Role of HLA compatibility in pediatric liver transplantation. Transplantation 1998; 66: 53-58.
11. Ozawa K, Uemoto S, Tanaka K, et al. An appraisal of pediatric liver transplantation from living relatives. Ann Surg 1992; 216: 547-554.
12. Zmijewski CM. Human leukocyte antigen matching in renal transplantation: Review and current status. J Surg Res 1985; 38: 66-87.
13. Takiff H, Cook DJ, Himaya HS, et al. Dominant effect of histocompatibility on ten-year kidney transplant survival. Transplantation 1988; 45: 410-415.
14. Knechtle SJ, Kalayoglu M, Alessandro AM, et al. Histocompatibility and liver transplantation. Surgery 1993; 114: 667-672.
15. Opelz G, Wujciak T, Dohler B, et al. HLA compatibility and organ transplant survival: Collaborative Transplant Study. Rev Immunogenet 1999; 1: 334-342.
16. Tanaka K, Inomata Y. Present status and prospects of living-related liver transplantation. J Hepatobiliary Pancreat Surg 1997; 4: 51-70.
17. Tanaka K, Uemoto S, Tokunaga Y, et al. Surgical techniques and innovations in living related liver transplantation. Ann Surg 1993; 217: 82-91.
18. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living related liver transplantation. Transplantation 1996; 61: 247-252.
19. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449-454.
20. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658-663.
21. Demetris A, Adams D, Bellamy C, et al. Update of international Banff schema for liver allograft rejection: Working recommendations for the histologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31: 792-799.
22. Terasaki PI, McClelland JD, Park MS, et al. Microdroplet assay of human serum cytotoxines. In: Ray JG, Hare DB, Pederson PD, Kayhoe DE, eds. Manual of Tissue Typing Techniques. Washington, DC, Department of Health, Education and Welfare Publications. 1974, pp 67-74.
23. Kiuchi T, Harada H, Matsukawa H, et al. One-way donor-recipient HLA-matching as a risk factor for graft-versus-host disease in living-related liver transplantation. Transpl Int 1998; 11: 383-384.
24. Prasad VK, Kernan NA, Heller G, et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999; 93: 399-409.
25. Kasahara M, Kiuchi T, Takakura K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: Clinical significance of humoral immunity in acute rejection. Transplantation 1999; 67: 568-575.
26. Connolly JK, Dyer PA, Martin S, et al. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 1996; 61: 709-714.
27. Thorogood J, van Houwelingen JC, van Rood JJ, et al. Factors contributing to long term kidney transplant in Eurotransplant. Transplantation 1992; 54: 152-158.
28. Smith DJ, Rose ML, Pomerance A, et al. Reduction of cellular rejection and increase in long-term survival after heart transplantation after HAL-DR matching. Lancet 1995; 346: 1318-1322.
29. Iwatsuki S, Rabin BS, Shaw BW, et al. Liver transplantation against T cell positive warm crossmatches. Transplant Proc 1984; 16: 1427-1429.
30. Moore SB, Wiesner RH, Perkins JD, et al. A positive lymphocyte crossmatch and major histocompatibility mismatching do not predict early rejection of liver transplants in patients treated with cyclosporine. Transplant Proc 1987; 19: 2390-2391.
31. Donaldson P, Undehill J, Doherty D, et al Influence of human leukocyte antigen matching on liver allograft survival and rejection: The dualistic effect. Hepatology 1993; 17: 1008-1015.
32. Steele D, Laufer TM, Smiley ST, et al. Two levels of help for cell alloantibody production. J Exp Med 1996; 183: 699-703.
33. Fung JJ, Zeevi A, Starzl TE, et al. Functional characterization of infiltrating T lymphocyte in human hepatic allografts. Hum Immunol 1986; 16: 182-199.
34. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32-38.
35. Dyer PA, Claas FH. A future for HLA matching in clinical transplantation. Eur J Immunogenet 1997; 24: 17-28.
36. Kiuchi T, Kasahara M, Uryuhara K, et al. Impact of graft-size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999; 67: 321-327.
37. Fujita S, Kim ID, Uryuhara K, et al. Hepatic grafts from live donors: Donor morbidity for 470 cases of live donation. Transpl Int 2000; 13: 333-339.
38. Hayashi M, Fujii K, Kiuchi T, et al. Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation. Transplant Proc 1999; 31: 403.
39. Singer PA, Siegler M, Whitington PF, et al. Ethics of liver transplantation using living donors. N Engl J Med 1989; 321: 620-622.
40. Ibrahim S, Dawson DW, Killenberg PG, et al. The pattern and phenotype of T-cell infiltration associated with human liver allograft rejection. Hum Pathol 1993; 24: 1365-1370.
41. Takakura K, Kiuchi T, Kasahara M, et al. Clinical implication of flow cytometry crossmatch with T or B cells in living donor liver transplantation. Clin Transplant 2001; 15: 309-316.
42. Hashikura Y, Kawasaki S, Terada M, et al. Long-term results of living-related donor liver transplantation: A single-center analysis of 110 transplants. Transplantation 2001; 72: 95-99.
43. Alonso EM, Piper JB, Echols G, et al. Allograft rejection in pediatric recipients of living related liver transplants. Hepatology 1996; 23: 40-43.
44. Gupta P, Hart J, Cronin D, et al. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72: 1098-1102.
45. Martin PJ, Petersdorf EW, Anasetti C, et al. HLA homozygosity and the risk of graft-versus-host disease. Tissue Antigens 1997; 50: 119-123.
46. Gorman TE, Julius CJ, Barth RF, et al. Transfusion-associated graft-vs-host disease: A fatal case caused by blood from an unrelated HLA homozygous donor. Am J Clin Pathol 2000; 113: 732-737.
47. Whitington PF, Rubin CM, Alonso EM, et al. Complete lymphoid chimerism and chronic graft-versus-host disease in an infant recipient of a hepatic allograft from an HLA-homozygous parental living donor. Transplantation 1996; 62: 1516-1519.
48. Scott I, O'Shea J, Bunce M, et al. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: Implications for unrelated bone marrow donor selection. Blood 1998; 92: 4864-4871.
49. Adorno D, Canossi A, Papola F, et al. Comparison between HLA class 1 PCR-ARMS and serologic typing in cadaveric kidney transplantation. Transplant Proc 1997; 29: 1423.